Moolec Science (MLEC) Income from Non-Controlling Interests (2022 - 2024)
Moolec Science (MLEC) reported Income from Non-Controlling Interests of -$2.3 million for Q4 2024, up 14.71% on a YoY basis from -$2.0 million in Q1 2024, and down 61.49% sequentially from -$1.4 million in Q3 2024.
Moolec Science (MLEC) Income from Non-Controlling Interests (2022 - 2024) Analysis & Trends
Moolec Science (MLEC) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$2.3 million in Q4 2024.
- For the quarter ending Q4 2024, Income from Non-Controlling Interests rose 14.71% year-over-year to -$2.3 million; the trailing twelve-month figure through Dec 2024 stood at $713470.0 (down 98.39% YoY), and the FY2024 full-year result was $107597.0, up 494.06% from the prior year.
- Income from Non-Controlling Interests eased to -$2.3 million in Q4 2024, from -$1.4 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $49.1 million in Q2 2023 to a low of -$48.0 million in Q4 2022.
- A 3-year average of -$1.4 million and a median of -$981450.5 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 399.34% in 2023, while the deepest fall reached 324.79% in 2023.
- Tracing MLEC's Income from Non-Controlling Interests over 3 years: stood at -$48.0 million in 2022, then soared by 94.44% to -$2.7 million in 2023, then gained by 14.71% to -$2.3 million in 2024.
- Business Quant data shows MLEC's Income from Non-Controlling Interests at -$2.3 million in Q4 2024, -$1.4 million in Q3 2024, and $5.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.27 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | 4.95 Mn |
| Mar 31, 2024 | -554,744.00 |
| Dec 31, 2023 | -2.67 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | 49.06 Mn |
| Mar 31, 2023 | -358,578.00 |
| Dec 31, 2022 | -47.96 Mn |
| Sep 30, 2022 | 721,426.00 |
| Jun 30, 2022 | -16.39 Mn |
| Mar 31, 2022 | 1.17 Mn |